Gregory Fraser
Stock Analyst at Truist Securities
(1.74)
# 3,200
Out of 4,893 analysts
36
Total ratings
53.85%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $62 → $65 | $66.14 | -1.72% | 9 | Apr 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $112.48 | +104.48% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $6.62 | +5.74% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.20 | +4,002.56% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $4.21 | +113.78% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $8.40 | -16.67% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $72.01 | -59.73% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $18.46 | +414.63% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $9.73 | +84.99% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $15.27 | +161.95% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Apr 21, 2025
Maintains: Hold
Price Target: $62 → $65
Current: $66.14
Upside: -1.72%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $112.48
Upside: +104.48%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $6.62
Upside: +5.74%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.20
Upside: +4,002.56%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $4.21
Upside: +113.78%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $8.40
Upside: -16.67%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $72.01
Upside: -59.73%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $18.46
Upside: +414.63%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $9.73
Upside: +84.99%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $15.27
Upside: +161.95%